Company profile
Abivax S.A. logo

Abivax S.A.

Pipeline1 asset

  • ObefazimodABX464 / microRNA-124 (miR-124) enhancer / Oral small molecule / Inflammatory diseases
    Moderately to severely active ulcerative colitisPhase 3ABTECT induction data readout completed July 2025; maintenance data expected Q2 2026Crohn's diseasePhase 2bENHANCE-CD initiated; 12-week induction data expected Q4 2026Moderately to severely active ulcerative colitis, combination therapyPreclinicalEvaluation of obefazimod combined with other agents; decision on combination agent expected in 2026

Latest news12 items

All news

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis Interim intent to treat (“ITT”) analysis from Study 108 supports strong

Interim Data • Phase 2presentation Fri, Jan 9, 2026

Abivax Announces Results of its May 11, 2026 Annual General Meeting

Abivax Announces Results of its May 11, 2026 Annual General Meeting PARIS, France – May 11, 2026 – 10:05 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the

Abivax to Present Data on Obefazimod at Digestive Disease Week®

Abivax to Present Data on Obefazimod at Digestive Disease Week ® Presentations Highlight Comprehensive Efficacy, Safety, and Patient-Reported Outcomes from the Phase 3 ABTECT Program and Preclinical Anti-Fibrotic Models in Inflammatory Bowel Disease PARIS, France – April 22, 2026 – 10:05 pm CEST –

Presentation / Abstract • Phase 3

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 22 abstracts presented at European Crohn’s and Colitis Organization’s (ECCO) 21 st Annual Congress illustrate the depth and breadth

Presentation / Abstract • Phase 3

Abivax Provides 2026 Corporate Outlook

Abivax Provides 2026 Corporate Outlook New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with obefazimod well positioned to become a future market leader in the IBD space ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on December 18, 2025,

Abivax to be Added to Nasdaq Biotechnology Index

Abivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – Abivax SA ( Euronext Paris : FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific Evidence: The acceptance of 1 oral presentation, 5 digital oral presentations and 16 posters

Presentation / Abstract • Phase 3

Abivax Presents Third Quarter 2025 Financial Results

Abivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025 ) with a cash runway into Q4 2027 PARIS, France , December 15, 2025 , 10:05 p.m. CET – Abivax SA ( Euronext Paris : FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”),

Abivax S.A. • Endpoint Arena